Literature DB >> 1540485

Interindividual variability in the N-sulphation of desipramine in human liver and platelets.

P Romiti1, L Giuliani, G M Pacifici.   

Abstract

1. The activity of N-sulphotransferase (N-ST) with desipramine (DMI) as substrate was measured in 118 human liver specimens, in platelets obtained from 105 subjects, in 12 specimens of human ileum and colon mucosa and in five specimens of human kidney and lung. 2. N-ST activity ranged between 5.71 and 157 pmol min-1 mg-1 protein in human liver and between 0.27 and 17.3 pmol min-1 mg-1 protein in human platelets. 3. Probit analysis was compatible with a unimodal distribution of the data from both liver and platelets. 4. The frequency distribution histograms of N-ST were asymmetric, with a positive skew in data from both liver and platelets. The mode, median and mean of N-ST were 16.4, 30.2 and 40.4 pmol min-1 mg-1 protein in liver, and 2.12, 3.61 and 3.82 pmol min-1 mg-1 protein in platelets, respectively. After logarithmic transformation of N-ST activity, the frequency distribution histogram was symmetric for data from both liver and platelets. 5. In extrahepatic tissues, the average (+/- s.d.) N-ST activity (pmol min-1 mg-1 protein) was 22.2 +/- 22.8 (ileum), 20.9 +/- 26.9 (colon), 12.4 +/- 5.5 (renal cortex), 9.3 +/- 2.8 (renal medulla) and 4.2 +/- 1.1 (lung). N-ST is widely distributed in the body and the intestine is the extrahepatic tissue with the highest N-ST activity.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1540485      PMCID: PMC1381194          DOI: 10.1111/j.1365-2125.1992.tb03995.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  28 in total

1.  Protein measurement with the Folin phenol reagent.

Authors:  O H LOWRY; N J ROSEBROUGH; A L FARR; R J RANDALL
Journal:  J Biol Chem       Date:  1951-11       Impact factor: 5.157

2.  Clinical significance of the sparteine/debrisoquine oxidation polymorphism.

Authors:  K Brøsen; L F Gram
Journal:  Eur J Clin Pharmacol       Date:  1989       Impact factor: 2.953

3.  Polymorphic debrisoquin hydroxylation in 757 Swedish subjects.

Authors:  E Steiner; L Bertilsson; J Säwe; I Bertling; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1988-10       Impact factor: 6.875

4.  Sulfation of minoxidil by human platelet sulfotransferase.

Authors:  G A Johnson; C A Baker
Journal:  Clin Chim Acta       Date:  1987-11-16       Impact factor: 3.786

Review 5.  The polymorphic oxidation of beta-adrenoceptor antagonists. Clinical pharmacokinetic considerations.

Authors:  M S Lennard; G T Tucker; H F Woods
Journal:  Clin Pharmacokinet       Date:  1986 Jan-Feb       Impact factor: 6.447

6.  Phenotypic consistency in hydroxylation of desmethylimipramine and debrisoquine in healthy subjects and in human liver microsomes.

Authors:  E Spina; C Birgersson; C von Bahr; O Ericsson; B Mellström; E Steiner; F Sjöqvist
Journal:  Clin Pharmacol Ther       Date:  1984-11       Impact factor: 6.875

7.  Interindividual variability in the glucuronidation and sulphation of ethinyloestradiol in human liver.

Authors:  A Temellini; L Giuliani; G M Pacifici
Journal:  Br J Clin Pharmacol       Date:  1991-06       Impact factor: 4.335

8.  Characterization of desmethylimipramine 2-hydroxylation in human foetal and adult liver microsomes.

Authors:  E Spina; G M Pacifici; C von Bahr; A Rane
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1986-04

9.  Genetic polymorphism in drug oxidation: in vitro studies of human debrisoquine 4-hydroxylase and bufuralol 1'-hydroxylase activities.

Authors:  A R Boobis; S Murray; C E Hampden; D S Davies
Journal:  Biochem Pharmacol       Date:  1985-01-01       Impact factor: 5.858

10.  Characterization of the common genetic defect in humans deficient in debrisoquine metabolism.

Authors:  F J Gonzalez; R C Skoda; S Kimura; M Umeno; U M Zanger; D W Nebert; H V Gelboin; J P Hardwick; U A Meyer
Journal:  Nature       Date:  1988-02-04       Impact factor: 49.962

View more
  9 in total

Review 1.  Molecular basis of polymorphic drug metabolism.

Authors:  A K Daly
Journal:  J Mol Med (Berl)       Date:  1995-11       Impact factor: 4.599

2.  Testosterone sulphation and glucuronidation in the human liver: interindividual variability.

Authors:  G M Pacifici; A Gucci; L Giuliani
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1997 Jul-Sep       Impact factor: 2.441

Review 3.  Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions.

Authors:  R J Bertz; G R Granneman
Journal:  Clin Pharmacokinet       Date:  1997-03       Impact factor: 6.447

4.  Minoxidil sulphation in human liver and platelets. A study of interindividual variability.

Authors:  G M Pacifici; R Bigotti; G Marchi; L Giuliani
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

Review 5.  Extrahepatic metabolism of drugs in humans.

Authors:  D R Krishna; U Klotz
Journal:  Clin Pharmacokinet       Date:  1994-02       Impact factor: 6.447

6.  Differences in cytochrome p450-mediated pharmacokinetics between chinese and caucasian populations predicted by mechanistic physiologically based pharmacokinetic modelling.

Authors:  Zoe E Barter; Geoffrey T Tucker; Karen Rowland-Yeo
Journal:  Clin Pharmacokinet       Date:  2013-12       Impact factor: 6.447

Review 7.  Individual variation in first-pass metabolism.

Authors:  Y K Tam
Journal:  Clin Pharmacokinet       Date:  1993-10       Impact factor: 6.447

8.  Interindividual variability of phenol- and catechol-sulphotransferases in platelets from adults and newborns.

Authors:  G M Pacifici; G Marchi
Journal:  Br J Clin Pharmacol       Date:  1993-12       Impact factor: 4.335

9.  Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine.

Authors:  K Brøsen; J G Hansen; K K Nielsen; S H Sindrup; L F Gram
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.